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ABSTRACT Augmented renal clearance (ARC) in critically ill patients can result
in suboptimal drug exposures and treatment failure. Combination dosage regi-
mens accounting for ARC have never been optimized and evaluated against Pseu-
domonas aeruginosa by use of the hollow-ﬁber infection model (HFIM). Using a P.
aeruginosa isolate from a critically ill patient and static-concentration time-kill ex-
periments (SCTKs), we studied clinically relevant piperacillin and tobramycin con-
centrations, alone and in combinations, against two inocula (105.8 and 107.6 CFU/
ml) over 72 h. We subsequently evaluated the effects of optimized piperacillin
(4 g every 4 h [q4h], given as 0.5-h infusions) plus tobramycin (5 mg/kg of body
weight q24h, 7 mg/kg q24h, or 10 mg/kg q48h, given as 0.5-h infusions) regi-
mens on killing and regrowth in the HFIM, simulating a creatinine clearance of
250 ml/min. Mechanism-based modeling was performed in S-ADAPT. In SCTKs, pip-
eracillin plus tobramycin (except combinations with 8 mg/liter tobramycin and against
the low inoculum) achieved synergistic killing (2 log10 versus the most active
monotherapy at 48 h and 72 h) and prevented regrowth. Piperacillin mono-
therapy (4 g q4h) in the HFIM provided 2.4-log10 initial killing followed by re-
growth at 24 h and resistance emergence. Tobramycin monotherapies displayed
rapid initial killing (5 log10 at 13 h) followed by extensive regrowth. As pre-
dicted by mechanism-based modeling, the piperacillin plus tobramycin dosage
regimens were synergistic and provided 5-log10 killing with resistance suppres-
sion over 8 days in the HFIM. Optimized piperacillin-tobramycin regimens pro-
vided signiﬁcant bacterial killing and suppressed resistance emergence. These
regimens appear to be highly promising for effective and early treatment, even
in the near-worst-case scenario of ARC.
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Infections caused by Gram-negative pathogens, such as Pseudomonas aeruginosa, incritically ill patients in intensive care units (ICUs) are posing a signiﬁcant challenge (1).
P. aeruginosa infections under conditions such as severe sepsis and septic shock are
associated with high rates of morbidity and mortality (2). Considerable pathophysio-
logical perturbations often occur in critically ill patients and can cause changes in renal
function, such as augmented renal clearance (ARC). ARC often leads to substantially
altered antibiotic pharmacokinetics (PK) (3–5), particularly for renally eliminated anti-
biotics, such as piperacillin and tobramycin, for which it results in substantially lower
exposures than those observed for the same dose in patients with normal renal
function (5–7). P. aeruginosa can rapidly develop resistance to antibiotics following
suboptimal exposures, which increases the risk of therapeutic failure (8, 9).
Given that this pathogen may cause serious infections in ICU patients, such as
bloodstream, intra-abdominal, and respiratory infections, including ventilator-associated
pneumonia, as well as its frequent development of multidrug resistance (MDR), there is
an urgent need to optimize antibiotic therapy (10–12). This situation is particularly
worrying for critically ill patients with ARC given the greater difﬁculty of achieving
optimal antibiotic exposures in these patients. Antimicrobial resistance rates in ICUs are
increasing, for reasons likely to include use of nonoptimized monotherapy or empiri-
cally chosen nonoptimized combination therapy (12, 13). This can result in increased
health care infection rates, prolonged hospitalization, and additional costs of
diagnostics and treatment (13–15). Rationally optimized antibiotic combination
therapy is considered a promising approach to maximize bacterial killing and
suppress the emergence of resistance in ICU patients, and ultimately to reduce this
health care burden (3).
Here we describe an approach to designing and evaluating optimized combination
dosage regimens of piperacillin and tobramycin, antibiotics that are commonly used
against P. aeruginosa in patients with ARC, for use in such patients. Our ﬁrst objective
was to quantify bacterial killing and suppression of resistance for combinations of
piperacillin and tobramycin against a P. aeruginosa ICU isolate by using static-
concentration time-kill experiments (SCTKs). The second objective was to optimize and
predict the effects of combination dosage regimens that maximize bacterial killing and
suppress resistance emergence for patients with ARC via a novel mechanism-based
model (MBM) (Fig. 1) developed based on the SCTK data. Third, we sought to evaluate
the effects of the optimized dosage regimens of piperacillin and tobramycin (alone and
in combination) on bacterial killing and resistance emergence of the clinical P. aerugi-
nosa strain in the hollow-ﬁber infection model (HFIM).
(Part of this work was presented as a talk at the Australasian Pharmaceutical Science
Association [APSA] and Australasian Society of Clinical and Experimental Pharmacolo-
gists and Toxicologists [ASCEPT] Joint Meeting, Brisbane, Australia, 5 to 8 December
2017.)
RESULTS
Static-concentration time-kill studies. At both tested inocula, tobramycin (MIC 
0.5 mg/liter) concentrations of 1 and 2 mg/liter produced rapid (within 5 h) initial killing
of 3.5 to 4.0 log10 CFU/ml followed by regrowth to levels close to growth control
values (Fig. 2). However, 8 mg/liter tobramycin yielded killing of 5.0 log10 CFU/ml at
48 h and suppressed regrowth to 3 log10 CFU/ml at 72 h. All tested piperacillin
(MIC  4 mg/liter) concentrations resulted in initial (within 5 h) killing of 1.8 to 2.3
log10 CFU/ml followed by rapid growth at the low inoculum but failed to provide any
killing at the high inoculum. Combinations of piperacillin with the two lowest concen-
trations of tobramycin were synergistic (2-log10 CFU/ml killing compared to that of
the most active monotherapy) at 72 h against both inocula (Fig. 2).
Mechanism-based mathematical modeling. The MBM simultaneously described
the effects of piperacillin, tobramycin, and the combination in the SCTKs and yielded
unbiased and precise curve ﬁts for all treatments (Fig. 2; see Fig. S1 in the supplemental
material). The coefﬁcient of correlation for the observed versus population-ﬁtted log10
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viable counts was 0.91. Subpopulation synergy was not sufﬁcient to characterize the
time course of bacterial killing and regrowth with combination dosage regimens.
Mechanistic synergy due to tobramycin enhancing the target site concentration of
piperacillin (i.e., via the permeabilizing effect of tobramycin on the bacterial outer
FIG 1 Structure of the mechanism-based model of bacterial growth and killing by the piperacillin (PIP) and
tobramycin (TOB) regimens alone and in combination. The ﬁrst population (PIPS/TOBS) was susceptible to
both piperacillin and tobramycin. The other two populations (PIPR/TOBI [piperacillin resistant and tobra-
mycin intermediate] and PIPI/TOBR [piperacillin intermediate and tobramycin resistant]) are not shown. A
life cycle growth model (68, 69) was utilized to describe the underlying biology of bacterial replication via
two states for each of the three populations. The maximum killing rate constants (Kmax) and the associated
antibiotic concentrations causing 50% of Kmax (KC50) are explained in Table 1. Mechanistic synergy (i.e.,
tobramycin enhancing the target site penetration of piperacillin) was applied to all three populations.
FIG 2 Fits (lines) of the developed MBM for observed (symbols) viable counts for piperacillin (PIP) and tobramycin
(TOB) alone and in various combinations against a P. aeruginosa ICU isolate (Pa1280) in in vitro static-concentration
time-kill experiments. Observed viable counts below the limit of counting (i.e., below 1.0 log10 CFU/ml) were
plotted as 0 log10 CFU/ml.
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membrane) (Fig. 1) was essential. Inclusion of mechanistic synergy for all three popu-
lations signiﬁcantly enhanced the model performance. Mechanistic synergy was ex-
pressed as an 3.5-fold decrease in the piperacillin concentration required for half-
maximal killing (KC50,PIP).
Optimization of combination dosage regimens. The in silico simulations wherein
the MBM developed from the SCTK data was applied to various dosage regimens
predicted no killing for all three regimens of piperacillin as monotherapy (Fig. 3).
Tobramycin monotherapies were predicted to provide killing of 3.5 to 3.8 log10 at
3 h, followed by extensive regrowth (Fig. 3). The lower daily dosage regimens of
piperacillin (i.e., 4 g every 8 h [q8h] and q6h) combined with tobramycin (i.e., 5 mg/kg
of body weight q24h, 7 mg/kg q24h, or 10 mg/kg q48h) were predicted to achieve
initial killing of 3 to 3.5 log10 at 24 h, followed by regrowth to the initial inoculum
(107.0 CFU/ml) at day 5 or 6. However, the combination of piperacillin at 4 g q4h plus
tobramycin at 5 mg/kg q24h, 7 mg/kg q24h, or 10 mg/kg q48h was predicted to
achieve 4.0-log10 killing and to suppress regrowth to below 5.5 log10 over 8 days
(Fig. 3).
In vitro hollow-ﬁber infection model. The observed pharmacokinetic proﬁles of
the HFIM samples adequately matched the target proﬁles for piperacillin and tobra-
mycin. Typical proﬁles showing the relationship between targeted and observed
concentrations are shown in Fig. S2 (the ﬁtted pharmacokinetic proﬁles were used in
the pharmacodynamic [PD] model). Changes in total and less-susceptible bacterial
populations are shown in Fig. 4 and 5. The growth control grew rapidly to 10.2 log10
CFU/ml, with less-susceptible populations for both piperacillin (on agar containing 12
or 20 mg/liter) and tobramycin (on agar containing 2.5 or 5 mg/liter) plateauing at 2
to 5 log10 CFU/ml. Piperacillin monotherapy provided 2.4-log10 killing at 13 h,
followed by regrowth with resistance by 24 h. Tobramycin monotherapies produced
killing of 3.1 to 7.1 log10 at 26 h, followed by rapid regrowth close to control values,
with ampliﬁcation of less-susceptible subpopulations, at 47 h (5 and 7 mg/kg q24h) and
95 h (10 mg/kg q48h). All three combination regimens produced nearly identical
extents of killing across the ﬁrst 7 days, with no viable colonies detected at 168 h.
Similarly, no viable colonies were detected at the end of day 8 (192 h) with the
FIG 3 Predicted viable count proﬁles for the indicated dosage regimens of piperacillin (PIP) and tobramycin (TOB) alone and in
combination via a novel mechanism-based model developed based on in vitro SCTK data.
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combinations containing tobramycin at 7 mg/kg q24h or 10 mg/kg q48h, while 3.7
log10 CFU/ml were observed with the combination containing tobramycin at
5 mg/kg q24h. For all three combinations, the only resistant colonies observed occurred
on agar containing tobramycin at 2.5 mg/liter, and only at 143 h (Fig. 5; Table S1). MICs
for colonies on antibiotic-containing agar plates indicated stable resistance (Table S2).
The mechanism-based model developed using the SCTK data was translated to
describe the time course of bacterial killing and regrowth in the HFIM (Fig. 4; Table 1).
The KC50,PIP for all three populations decreased by 2.3-fold in the presence of 32
mg/liter tobramycin compared to the KC50,PIP in the absence of tobramycin. The
model-estimated tobramycin concentration required for half-maximal permeabilization
of the outer membrane (IC50,OM,TOB) was 4.7 mg/liter (Table 1).
DISCUSSION
Critically ill patients with ARC are at potential risk of therapeutic failure and
resistance emergence due to suboptimal antibiotic exposures (7, 16–19). However,
combination regimens have never been optimized for ARC and may provide improved
antibiotic activity compared to what is possible with monotherapy. A novel MBM (i.e.,
developed based on the SCTK data) was used to perform in silico simulations for
patients with ARC. Our simulations predicted a lack of killing for all three piperacillin
monotherapies (4 g q8h, q6h, or q4h). This was similar to our previously reported results
of these monotherapies providing very limited killing in the HFIM (19). Tobramycin
monotherapies were predicted by the MBM to achieve initial killing over 24 h, followed
by regrowth and resistance emergence. In contrast, combination regimens containing
piperacillin at 4 g q4h plus tobramycin were predicted to substantially enhance
bacterial killing and to minimize resistance emergence over 8 days against P. aeruginosa
isolate Pa1280. Subsequently, treatment regimens simulated in silico were experimen-
tally evaluated in the HFIM.
For -lactam antibiotics, including piperacillin, the extent of bacterial killing and the
clinical efﬁcacy were found to be associated with the cumulative percentage of the
24-h dosing interval that the free, i.e., unbound, concentration of drug exceeded
the MIC for the infecting pathogen under steady-state pharmacokinetic conditions
(fTMIC) (20, 21). An fTMIC target of 50% for piperacillin has been shown to be
necessary for near-maximal bacterial killing in 24-h in vivo infection model studies
(20–22). However, an HFIM study with piperacillin-tazobactam and retrospective clinical
studies with piperacillin-tazobactam and other -lactams suggested that higher targets
(100% fT5MIC, 100% fTMIC, and 100% fT4MIC, respectively) may be required for
bacterial killing and resistance suppression in serious infections (19, 23–26). Several
clinical studies indicated that patients with ARC are at particular risk of treatment failure
and rapid resistance emergence due to subtherapeutic -lactam concentrations (7,
16–19). In agreement with the above studies, piperacillin at 4 g q4h as monotherapy
resulted in very limited killing and in extensive regrowth despite achieving 100% fTMIC
in this HFIM study simulating ARC (Fig. 4).
FIG 4 Population ﬁts (lines) of the mechanism-based PK/PD model for observed (symbols) viable count proﬁles of
the total population for the indicated piperacillin-tobramycin regimens against Pa1280 in the HFIM. Observed
viable counts below the limit of counting (i.e., below 1.0 log10 CFU/ml) were plotted as 0 log10 CFU/ml.
Optimized Regimens and Hollow-Fiber Infection Model Antimicrobial Agents and Chemotherapy
May 2018 Volume 62 Issue 5 e00078-18 aac.asm.org 5
 o
n
 M
ay 10, 2018 by UQ Library
http://aac.asm
.org/
D
ow
nloaded from
 
Two PK/PD indices, the area under the unbound drug concentration-time curve
divided by the MIC (fAUC/MIC) and the maximum unbound drug concentration divided
by the MIC (fCmax/MIC), have been used as predictors of bacterial killing by amin-
oglycosides (e.g., tobramycin) (21, 27–29). The fCmax/MIC relies on the concentration at
a single time point within a dosage interval. The fAUC/MIC, which has most commonly
been used to predict bacterial killing by aminoglycosides, considers the total exposure
across a 24-h period. An in vitro study (30) showed that tobramycin monotherapy even
at an fAUC/MIC of 168, which was 4 times the suggested fAUC/MIC breakpoint of 42 for
bactericidal effect (31), did not inhibit the regrowth of bacteria at the initial inoculum
of 106.0 CFU/ml against all three evaluated P. aeruginosa strains. An fAUC/MIC of 168
would be expected to be achieved for MICs of up to 0.5 mg/liter following a
tobramycin dose of 5 to 6 mg/kg in critically and noncritically ill patients with normal
renal function (32, 33). In agreement with these studies, tobramycin monotherapies of
5 or 7 mg/kg q24h or 10 mg/kg q48h (with fAUC/MIC ratios of 62 to 125 for patients
with ARC [34] and a tobramycin MIC of 0.5 mg/liter) achieved considerable killing over
FIG 5 Effects of each piperacillin (PIP) and tobramycin (TOB) dosage regimen on the total bacterial population and less-susceptible
populations (i.e., able to grow in the presence of 3 or 5 the piperacillin MIC and 5 or 10 the tobramycin MIC) in the HFIM. Nearly
complete suppression of less-susceptible subpopulations was seen on antibiotic-containing agar plates for combination regimens as
opposed to monotherapies of piperacillin and tobramycin. No colonies were observed on antibiotic-containing agar plates for the
combinations, except at 143 h. Observed viable counts below the limit of counting (i.e., below 1.0 log10 CFU/ml for the total population
and below 0.7 log10 CFU/ml for less-susceptible populations) were plotted as 0 log10 CFU/ml.
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24 h, followed by substantial regrowth over 8 days, in our HFIM simulating ARC. This
ﬁnding was also consistent with bacterial killing and regrowth predicted by the MBM
developed from the SCTK data.
In contrast to the monotherapies, our optimized combination dosage regimens
(piperacillin at 4 g q4h with tobramycin at 5 mg/kg q24h, 7 mg/kg q24h, or 10 mg/kg
q48h) demonstrated synergistic killing and suppression of regrowth over 8 days. The
suppression of less-susceptible populations by the combinations was conﬁrmed by the
nearly complete absence of colonies on antibiotic-containing agar plates. These ﬁnd-
ings from the HFIM were consistent with the predictions from our MBM, indicating
successful translation from SCTKs to the dynamic HFIM. This highlights the utility of the
MBM for selecting optimized regimens that maximize bacterial killing of and minimize
resistance emergence in P. aeruginosa. The latter is an especially important ﬁnding
given that P. aeruginosa can rapidly develop MDR.
Several in vitro SCTK and checkerboard studies have shown synergy for piperacillin-
tobramycin against P. aeruginosa (35–39). A small number of dynamic HFIM and in vivo
infection model studies conducted using other -lactam plus aminoglycoside combi-
nations have also demonstrated beneﬁcial effects against P. aeruginosa (40–43). An
open-label, randomized, multicenter study showed that piperacillin-tazobactam plus
TABLE 1 Parameter estimates for the piperacillin-tobramycin combination model against clinical P. aeruginosa ICU isolate Pa1280a
Parameter (unit) Symbol Population mean (SE [%])
Initial inoculum (log10 CFU/ml) Log CFU0 7.47 (2.67)
Maximum population size (log10 CFU/ml) Log CFUmax 9.64 (1.29)
Replication rate constant (h1) k21 50 (ﬁxed)
Mean generation time (min)
PIPs/TOBs k12,SS1 57.5 (7.8)
PIPR/TOBI k12,RI1 180 (6.6)
PIPI/TOBR k12,IR1 57.5 (7.8)
Log10 mutant frequencies
PIP LogMUT,PIP 4.69 (2.01)
TOB LogMUT,TOB 6.67 (2.55)
Bacterial killing by PIP
Maximum killing rate constant (h1) Kmax,PIP 0.31 (10.1)
PIP concn causing 50% of Kmax,PIP (mg/liter)
PIPs/TOBs KC50,SS,PIP 1.49 (13.6)
PIPR/TOBI KC50,RI,PIP 58.4 (9.51)
PIPI/TOBR KC50,IR,PIP 5.01 (11)
Hill coefﬁcient for PIP HillPIP 2.18 (3.4)
Inhibition of probability of successful replication by PIP (InhREP)
Maximum inhibition Imax,REP 1.0 (ﬁxed)
Concn causing 50% of Imax,REP (mg/liter)
PIPs/TOBs IC50,SS,REP 0.911 (11)
PIPR/TOBI IC50,RI,REP 163 (14.6)
PIPI/TOBR IC50,IR,REP 163 (14.6)
Hill coefﬁcient for inhibition of successful replication HillREP 3.61 (11)
Bacterial killing by TOB
Maximum killing rate constant (h1)
PIPs/TOBs Kmax,SS,TOB 7.79 (7.8)
PIPR/TOBI Kmax,RI,TOB 15 (11.1)
PIPI/TOBR Kmax,IR,TOB 7.79 (7.8)
Tobramycin concn causing 50% of Kmax,TOB (mg/liter)
PIPs/TOBs KC50,SS,TOB 0.072 (16.2)
PIPR/TOBI KC50,RI,TOB 1.01 (8.9)
PIPI/TOBR KC50,IR,TOB 311 (10.5)
Permeabilization of the outer membrane by TOB
Maximum fractional decrease of KC50,PIP by TOB via outer membrane disruption Imax,OM,TOB 0.656 (32.6)
TOB concn causing 50% of Imax,OM,TOB (mg/liter) IC50,OM,TOB 4.7 (2.4)
SD of residual error on log10 scale SDCFU 0.52 (29.7)
aPIP, piperacillin; TOB, tobramycin.
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tobramycin was more effective than, yet as safe as, ceftazidime plus tobramycin in the
treatment of patients with nosocomial lower respiratory tract infection (44). However,
our study is the ﬁrst to evaluate the impact of a combination dosage regimen
optimized for patients with ARC on bacterial killing and resistance of P. aeruginosa.
Furthermore, the extent and time course of bacterial killing and regrowth for such a
regimen have not been characterized by use of an MBM.
MBM results revealed that the piperacillin concentration required for half-maximal
killing of the piperacillin-resistant population (KC50,RI,PIP; 58.4 mg/liter for monotherapy)
was considerably higher than that for the susceptible population (KC50,SS,PIP; 1.49
mg/liter for monotherapy). Also, a higher tobramycin concentration was required for
half-maximal killing of piperacillin-resistant populations (KC50,RI,TOB; 1.01 mg/liter) than
for half-maximal killing of the susceptible population (KC50,SS,TOB; 0.072 mg/liter). The
outer membrane of P. aeruginosa presents a formidable barrier (45, 46), and its
disruption is likely to enhance the target site penetration of piperacillin (47, 48). The
synergy mechanism proposed by our mechanism-based PK/PD model (i.e., tobramycin
permeabilizing the bacterial outer membrane) is in agreement with electron micro-
graphs of ultrastructural damage, loss of cytosolic green ﬂuorescent protein (GFP) from
a GFP-expressing strain, and nitroceﬁn uptake results from our recently published
studies (49). This was expressed in the MBM as a considerable decrease in the KC50,PIP
against all three bacterial populations.
Our results clearly demonstrate that optimized combination dosage regimens
achieved substantial killing and suppression of emergence of resistance when sub-
jected to the pharmacokinetics found in the clinical scenarios of ARC. In a large part of
the world, short-term infusions remain the standard method of administration for
-lactams, including piperacillin-tazobactam, as demonstrated by two recent studies
including up to 53 countries (50, 51). However, prolonged infusions are used in other
countries. Therefore, evaluation of the proposed combination dosage regimens with
prolonged infusion of piperacillin-tazobactam may be considered for future studies.
A limitation of the present study was the use of a single isolate, which was not
molecularly characterized. The complex nature and expense of the HFIM preclude
testing of large numbers of different strains. Therefore, the vast majority of HFIM
studies in the recent literature used one strain and replicate (52–57). Given that the
HFIM system lacks an immune system, our results may best predict the activity of
antibiotic regimens in immunocompromised patients, often seen in ICUs, and may be
extended to other, similar patients, such as those in transplant units. Predictions
speciﬁcally for immunocompetent patients may be addressed in the future by simula-
tions with an MBM that includes an effect of the immune system based on data from
animal models (58, 59).
In summary, the ﬁndings from the HFIM were consistent with the MBM-predicted
bacterial killing and regrowth and therefore translated well from SCTKs to the dynamic
hollow-ﬁber infection model. The synergistic effect was modeled via an increased
target site penetration of piperacillin, likely due to disruption of the bacterial outer
membrane by tobramycin. Optimized piperacillin-tobramycin combination regimens
that accounted for ARC provided signiﬁcant bacterial killing and suppressed the
emergence of resistance in the HFIM against a P. aeruginosa ICU isolate. Thus, these
regimens should be considered for future evaluation in patients with ARC to provide
guidance on effective and early treatment in ICUs.
MATERIALS AND METHODS
Bacterial isolate, antibiotics, media, and susceptibility testing. A clinical isolate of P. aeruginosa
(Pa1280) was obtained from a critically ill patient with a severe soft tissue infection (Royal Brisbane and
Women’s Hospital, Brisbane, Queensland, Australia). Stock solutions of piperacillin-tazobactam (4 g of
piperacillin-0.5 g of tazobactam per vial; Aspen, New South Wales, Australia) and tobramycin (AK
Scientiﬁc, Inc., Union City, CA) were prepared in sterile distilled water and ﬁlter sterilized by use of a
Millex-GV 0.22-m polyvinylidene diﬂuoride (PVDF) syringe ﬁlter (Merck Millipore Ltd., Cork, Ireland).
Stocks were stored at 80°C and thawed immediately prior to each experiment. The in vitro SCTK and
dynamic HFIM studies were performed using cation-adjusted Mueller-Hinton broth (CAMHB; BBL, BD,
Sparks, MD). Drug-containing agar plates were prepared by adding piperacillin-tazobactam or tobramy-
Yadav et al. Antimicrobial Agents and Chemotherapy
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cin stock solution to cation-adjusted Mueller-Hinton agar (CAMHA; BD, Sparks, MD, USA). Viable counting
was performed on CAMHA (containing 25 mg/liter Ca2 and 12.5 mg/liter Mg2). The MICs (piperacillin
MIC  4 mg/liter; tobramycin MIC  0.5 mg/liter) were determined in triplicate according to the Clinical
and Laboratory Standards Institute guidelines (60), with EUCAST breakpoints used to deﬁne antibiotic
susceptibility and resistance (61).
Static-concentration time-kill experiments. Clinically relevant concentrations of piperacillin (12, 24,
and 75 mg/liter) and tobramycin (1, 2, and 8 mg/liter) were studied as monotherapies and in combina-
tions. The concentrations included the simulated steady-state average and peak concentrations of
unbound drug in plasma for patients with ARC following standard and highest approved doses (5, 19,
34). SCTKs were performed with low (105.8 CFU/ml) and high (107.6 CFU/ml) initial inocula as
described previously (62, 63). Serial broth samples were taken 5 to 10 min before dosing (i.e., at 0 h) and
at 1.5, 3, 5, 24, 29, 48, and 72 h. At 24 and 48 h, bacterial suspensions were centrifuged (10 min, 3,220 
g, 36°C), the supernatant was carefully removed, and bacteria were resuspended in fresh, prewarmed
broth with the targeted antibiotic concentrations. All bacterial samples were washed twice in sterile
saline, with serial dilution (1:10) performed via the addition of 100 l of an undiluted bacterial suspension
to 900 l of sterile saline. Viable counts were determined by manually plating 100 l of an undiluted or
appropriately diluted suspension in saline onto CAMHA plates (62–64). Agar plates were incubated at
36°C for 48 h, and colonies were counted manually.
Mechanism-based population PK/PD modeling. Mechanism-based modeling (MBM) of SCTK data
at both inocula was performed utilizing S-ADAPT (version 1.57) (importance sampling; pmethod 4) (65,
66) and SADAPT-TRAN (67). The MBM utilized a life cycle growth model to describe the underlying
biology of bacterial replication (68, 69). In this modeling analysis, we evaluated two types of synergistic
interactions: (i) subpopulation synergy, where piperacillin kills the tobramycin-resistant subpopulations
and vice versa; and (ii) mechanistic synergy, which occurs with tobramycin enhancing the killing by
piperacillin (Fig. 1). Mechanistic synergy was incorporated into the model by assuming an increase in
target site penetration of piperacillin due to disruption of the outer membrane by tobramycin (70–72).
Competing models were evaluated based on the S-ADAPT objective function value (1 log likelihood),
standard diagnostic plots, the coefﬁcient of correlation, and visual predictive checks (73, 74). The
differential equations are available in the supplemental material. The MBM developed based on the SCTK
data was adapted for the HFIM studies; all drug concentrations and all viable count proﬁles in the HFIM
were ﬁtted by the ﬁnal model.
In silico simulations informing choice of dosage regimens for further evaluation. The MBM
developed based on SCTK data combined with the pharmacokinetics of piperacillin and tobramycin for
patients with ARC (creatinine clearance  250 ml/min) was used in in silico simulations to predict
bacterial responses (viable counts) to various clinically relevant dosage regimens of each drug alone and
in combination (5, 19, 34). The total body clearance and half-life were 43 liters/h and 0.80 h, respectively,
for piperacillin and 12.9 liters/h and 1.07 h, respectively, for tobramycin (5, 19, 34). The simulated dosage
regimens were piperacillin at 4 g every 4 h (q4h), q6h, or q8h, given as 0.5-h infusions, and tobramycin
at 5 mg/kg q24h, 7 mg/kg q24h, or 10 mg/kg q48h, given as 0.5-h infusions. All in silico simulations were
performed at an initial inoculum of 107.0 CFU/ml by using Berkeley Madonna (v8.3.18). Based upon the
results of the simulations, the following regimens were chosen for evaluation in the HFIM: piperacillin at
4 g q4h, given as 0.5-h infusions, and tobramycin at 5 mg/kg q24h, 7 mg/kg q24h, or 10 mg/kg q48h,
given as 0.5-h infusions. An untreated control was included.
In vitro hollow-ﬁber infection model. The setup of the HFIM has been described previously (19, 52).
In brief, cellulosic cartridges (batch B720170715b; FiberCell Systems Inc., Frederick, MD, USA) were used,
and the HFIM system was maintained at 36°C in a humidiﬁed incubator. An initial inoculum of 107.0
CFU/ml was prepared as described previously (19, 52). Bacterial samples were collected at 0, 1.5, 5, 7, 13,
23, 26, 31, 47, 71, 95, 119, 143, 167, and 191 h. Viable counts for total populations were determined as
described above for the SCTKs. PK samples (1.0 ml) were collected in duplicate from the outﬂow of the
central reservoir of the HFIM at various times (0.66, 1, 1.5, 3.5, 5, 7, 8.66, 13, 23, 24.66, 31, 47, 71, 72.66,
95, 119, 143, 167, and 191 h) throughout the experiment and were placed into cryovials. All samples were
immediately stored at 80°C until assay. In order to quantify the bacterial populations less susceptible
to piperacillin and tobramycin before and during treatment, mutant frequencies were determined at
baseline (i.e., 0 h) and at 23, 47, 95, 143, and 191 h. The bacterial counts of less-susceptible populations
were determined by plating 200-l bacterial samples on agar plates supplemented with piperacillin at
3 and 5MIC (i.e., 12 and 20 mg/liter) and with tobramycin at 5 and 10MIC (i.e., 2.5 and 5 mg/liter).
Agar plates were incubated for 2 days. The limit of counting was 1.0 log10 CFU/ml (i.e., one colony per
plate) for antibiotic-free plates and 0.7 log10 CFU/ml for antibiotic-containing plates. The log10 mutant
frequency (log10 MF) was determined as follows: log10 MF  log10 (CFU/ml on antibiotic-containing
agar)  log10 (CFU/ml on antibiotic-free agar). MICs were determined at 0, 47, 143, and 191 h by taking
a subset of at least three colonies from antibiotic-free and antibiotic-containing plates.
Antibiotic assays for pharmacokinetics. Concentrations of piperacillin were measured in CAMHB at
ambient temperature by use of a validated high-performance liquid chromatography–ultraviolet (HPLC-
UV) method as described previously (19). The HPLC-UV system consisted of a Shimadzu Prominence
LC-20AD liquid chromatograph, an SIL-20ACHT autosampler, and an SPD-20A UV detector (Shimadzu,
Tokyo, Japan). The precision was within 11.7% and the accuracy within 4.4% at 5, 20, and 150 mg/liter
of piperacillin. Concentrations of tobramycin were measured in CAMHB by use of an immunoassay.
Analysis was conducted by Pathology, Queensland, Australia, by use of a Synchron system and a
tobramycin kit (Beckman Coulter, Galway, Ireland). Test samples were assayed alongside CAMHB cali-
brators and quality controls. Some samples were diluted to ﬁt within the calibration range. Observations
Optimized Regimens and Hollow-Fiber Infection Model Antimicrobial Agents and Chemotherapy
May 2018 Volume 62 Issue 5 e00078-18 aac.asm.org 9
 o
n
 M
ay 10, 2018 by UQ Library
http://aac.asm
.org/
D
ow
nloaded from
 
below the limit of quantiﬁcation are for undiluted samples. Measured results were realigned using
CAMHB calibrators. For all tobramycin samples, accuracy and precision were found to be within 10% of
expected values, with only a few exceptions at the lower limit of quantiﬁcation (0.2 mg/liter) (	15 to
20%).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC
.00078-18.
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